AbbVie's 3-Year Drug Price Deal with White House and R&D Pledge
CNBC TelevisionJanuary 13, 20261 min867 views
5 connections·7 entities in this video→AbbVie's Agreement with the White House
- 🤝 AbbVie has finalized a three-year agreement with the White House aimed at lowering drug prices.
- 💡 In exchange for this deal, AbbVie is reportedly receiving an exemption from tariffs.
Research and Development Commitment
- 🔬 As part of the agreement, AbbVie is pledging $100 billion over the next 10 years specifically for research and development within the United States.
Broader Context of Drug Pricing
- 📈 This development is part of a larger narrative surrounding drug affordability, a key issue the Trump administration has been addressing.
- 🎯 The administration has previously secured similar deals with other pharmaceutical companies like Merck, Roche, and Gilead in December.
Knowledge graph7 entities · 5 connections
How they connect
An interactive map of every person, idea, and reference from this conversation. Hover to trace connections, click to explore.
Hover · drag to explore
7 entities
Chapters1 moments
Key Moments
Transcript4 segments
Full Transcript
Topics8 themes
What’s Discussed
AbbVieWhite HouseDrug PricesTariffsResearch and DevelopmentPharmaceutical CompaniesDrug AffordabilityTrump Administration
Smart Objects7 · 5 links
Companies· 7